Search Results 341-350 of 14780 for anti-TNF drugs

1. Cancer treatment myths: Any truth to these common beliefs? - Mayo Clinic

   This may lead to the cancer cells no longer responding to the chemotherapy drugs or radiation treatments that were given initially. Myth: Drug companies and the ...

2. Tetanus Immune Globulin (Intramuscular Route) Description and Brand Names - Mayo Clinic

   Description and Brand Names. Drug information provided by: Merative, Micromedex®. US Brand Name. Baytet; HyperTET SD. Descriptions.

3. Pneumococcal Vaccine Polyvalent (Intramuscular Route, Subcutaneous Route) Before Using - Mayo Clinic

   Drug Interactions. Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an ...

4. Interferon Alfa-2b (Injection Route) Side Effects - Mayo Clinic

   Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for ...

5. Diclofenac (Topical Application Route) Side Effects - Mayo Clinic

   Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

6. Infliximab-Abda (Intravenous Route) Side Effects - Mayo Clinic

   Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

7. Blood pressure medications: Can they raise my triglycerides? - Mayo Clinic

   Yes, some blood pressure medicines can affect triglyceride and cholesterol levels. These include certain diuretics and beta blockers.

8. Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer - Mayo Clinic

   ... anti-tumor necrosis factor [anti-TNF] agents) within 6 weeks prior to cycle 1 day 1: Patients who have received acute, low dose, systemic immunosuppressant ...

9. Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) - Mayo Clinic

   Demonstrated intolerance or inadequate response to one or more anti-tumor necrosis factor (TNF) therapies. Exclusion Criteria: Current diagnosis of ...

10. A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors - Mayo Clinic

    Drugs & Supplements A-Z · Health Books · Healthy Living Program · Mayo Clinic Health ... treatment with an anti LAG-3 or anti TIM-3 is also excluded; Known ...